GRIbenzinga

GRI Bio Reported Interim 2-Week Safety Results From Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 1, 2025 by benzinga

GRI Bio Reported Interim 2-Week Safety Results From Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis | GRI Stock News | Candlesense